| Identification | Back Directory | [Name]
SKQ1 Bromide | [CAS]
934826-68-3 | [Synonyms]
PDTP
CS-2582
Visomitin
SKQ1 Bromide
SKQ1(Visomitin)
Visomitin(SKQ1)
SKQ1;SKQ 1;SKQ-1
SKQ1 Bromide, SKQ1
SKQ1 Bromide (Visomitin)
Visomitin (Synonyms: SKQ1)
SKQ 1,inhibit,Visomitin,SKQ-1,Inhibitor,Reactive Oxygen Species
(10-(4,5-Dimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)decyl)triphenylphosphonium bromide | [EINECS(EC#)]
604-604-1 | [Molecular Formula]
C36H42BrO2P | [MDL Number]
MFCD29477502 | [MOL File]
934826-68-3.mol | [Molecular Weight]
617.62 |
| Chemical Properties | Back Directory | [storage temp. ]
Hygroscopic, -20°C Freezer, Under inert atmosphere | [solubility ]
Chloroform (Slightly), Methanol (Slightly) | [form ]
Solid | [color ]
Brown |
| Hazard Information | Back Directory | [Description]
SKQ1 (bromide) is a mitochondria-targeted antioxidant that decreases transmembrane potential and production of reactive oxygen species (ROS).1 SKQ1 prevents neuronal loss and synaptic damage in a rat model of spontaneous Alzheimer’s disease, as well as decreases severity of arthritic lesions in rats.2,3 SKQ1 slows development of age-related ocular pathologies in murine, porcine, bovine, and canine model systems.4 It also prevents acute phenoptosis following rhabdomyolysis, stroke, and myocardial infarction.5,6,7 | [Uses]
Visomitin is a mitochondria-targeted antioxidant with the ability to delay some manifestations of aging. | [in vivo]
Regarding systemic angiogenic factors, it is observed in serum of Pancreatic ductal adenocarcinoma (PDAC) bearing mice a decrease in KC in the group of continuous treatment with Visomitin (SkQ1). Treatment of the mice with Visomitin increases the level of VEGF molecules. The amount of MIP1a and prolactin is reduced in all Visomitin treatment groups or after the follow-up treatment, respectively. Also, an increase in the IL-6 and IL-13 amount is found in the Visomitin treated groups. TGF-b amount is decreased in the pretreatment setting. On the contrary, all schemes of the Visomitin treatment decrease the NKT cell percentage. The Visomitin treatment has prolonged the median survival of PDAC-bearing mice, but the difference does not reach the level of significance defined[1]. |
|
|